Drugs / BESILESOMAB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04856215 | Sep 2023 → Sep 2025 | leukemia | Great Ormond Street Hospital for Children NHS Foundation Trust | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BESILESOMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108021 ↗ |
| Known as | BW 250/183 | “The Investigational Medicinal Product (IMP) consist of 1) 111Indium- and 2) 90Yttrium-labelled anti-CD66 (BW250/183) monoclonal antibody.” NCT04856215 ↗1“BW 250/183 anti-CD66 is a murine IgG1 kappa monoclonal antibody, originally produced as an anti-CEA antibody.” NCT04856215 ↗ |
| Modality | Monoclonal antibody | “murine IgG1 monoclonal antibody” NCT04856215 ↗ |
| Route | Intravenous | “once infused in the blood” NCT04856215 ↗ |